Medopad, a UK-based health tech company specializing in artificial intelligence (AI), announced on February 2, 2018 over £100 million (€113m; US$140m) of commercial projects and partnerships in China. The group will notably partner with Internet giant Tencent to deliver medical AI solutions globally.
The UK firm was part of UK Prime Minister Theresa May’s trade delegation to China, the PM’s first official visit to the country.
Medopad has 15 trade deals with Chinese organizations
Medopad has signed fifteen trade deals with leading Chinese organizations. The main agreements concluded by the British company include:
- A partnership with Tencent Holdings, one of China’s largest technology businesses, to develop the use of artificial intelligence (AI) in healthcare platforms for research impact and clinical decision support.
- A collaboration with Peking University to configure new models of care and patient monitoring solutions. This project will be part of a £75 million (€85m; US$105m) investments in projects funded by government, hospitals and other enterprises.
- A £36 million (€41m; US$50m) deal with China Resources to improve the management of patients with chronic and high cost diseases are cared for. It will be deployed in 600 hospitals over five years.
- A contract with Ping An Good Doctor, an online-to-offline healthcare servicing platform, to explore deploying Medopad’s technology, alongside their advanced AI, supporting delivery of remote monitoring to a cohort of their chronic and high cost disease patients from their 200 million user base.
- A project with Lenovo New Vision to explore new types of wearable technology in order to empower remote patient monitoring.
- An alliance with the National Clinical Research Centre for Geriatric Disorders. The purpose of its partnership is to use Medopad’s patient monitoring and AI capabilities to better deliver care to their millions of patients with Parkinson’s and Alzheimer’s disorders.
Other organizations with which Medopad has partnered include: Actelion, UMP Healthcare, Johnson & Johnson Vision Care (Shanghai), GSK China, Accenture, Royal Free NHS Trust, and Chelsea Football Club.
USD130 million raised in first round of financing
Medopad also announced the first close of its Series A USD130 million (€105 million) fund raise round. The USD20 million (€16m) capital raise received participation from a number of global family offices and institutional investors including China’s NWS Holdings.
Medopad: one of the market leader in predictive analytics
« Modern medical advancements are at a stage where prediagnostics and analytics for disease prevention are as prevalent and important as ever before, » said Brian Cheng, executive director at NWS Holdings (source: Asiaone.com). « Medopad is already well positioned to capture this growing demand through its continuous involvement with rare disease patients and helping medical institutions treat patients in a more efficient and cost effective manner. We believe Medopad will succeed in revolutionising the current convoluted methods of disease treatment and prevention into a more succinct ecosystem with the development of its artificial intelligence and big data gathering capabilities. »
Two healthcare industry pioneer joined the company’s management
« We now have several amazing strategic investors in the business, which is a great achievement for us as we gear for significant growth and scale our business, » said Dan Vahdat, CEO of Medopad. « Managing population health is one of the greatest challenges for governments across the world. As such, the investment appetite for solutions that address and manage this concern is substantial. We are proud to be at the forefront of solving this problem and supporting people around the world. »
In addition, Medopad announced the appointment of healthcare industry pioneers Stuart Fletcher and Simon MacKinnon OBE as non-Executive Directors, bringing strong healthcare and international business expertise to the Medopad board of directors.